Articles

Dr Gunther Grabner, professor of ophthalmology at the Paracelsus University of Salzburg, conducted a survey on the advantages and limitations of femtosecond lasers, and concluded that they will come to replace microkeratomes fully.

In a worldwide first, Dr Luis Ruiz presented the preliminary clinical results of an ongoing pilot study concentrating on the non-invasive intrastromal correction of presbyopia.

During the "Controversies in Cataract and Refractive Surgery" symposium, Dr Jack Holladay and Dr Theo Seiler debated the relative merits of presbyopia treatments.

Bimanual microincision cataract surgery (MICS) and microaxial phacoemulsification provide optically better incisions but bimanual MICS respects corneal prolateness more than microaxial phaco, Professor Jorge Alió told delegates.

Recent acquisitions, division restructuring, and management changes prove that Carl Zeiss Meditec is very much committed to change. Ophthalmology Times Europe spoke with new CEO, Dr Michael Kaschke, about the challenges that he faces in an ever-evolving market.

Schwind and Zeimer are to cooperate to supply an integrated all-laser LASIK solution.

As the human eye is not geometrically round, biometry is required for proper sizing of phakic IOLs, Dr Liliana Werner told delegates in a presentation entitled 'Phakic IOLs: a report from the pathology lab'.

Dr Amar Agarwal and team describe a technique for adhering sutureless scleral-fixated IOLs with a biological fibrin sealant glue.

The SERPING1 gene code influences the likelihood of developing age-related macular degeneration (AMD), according to study results published online ahead of print by The Lancet.

Dr Alberto Villarrubia gives an overview of the new Artifical Anterior Chamber for the Amadeus II machine as a way to extract donor lamellae.

Monovision offers a safe and an effective option while multifocals are a high risk strategy, Dr Graham D. Barrett controversially told delegates during a session that discussed whether surgeons should introduce multifocal IOLs (MFIOLs) into their practice.

AMO's Healon viscoelastic and Hoya's iSpheric IOL

A standardized language of trauma classification can have value for prognosis as well as description, according to Dr Dante Pieramici.

Dr Philippe Denis & Dr Thierry Zeyen explain why they feel that a new fixed combination, Azarga, could soon become the therapy of choice.

Dr Claus Eckardt discusses the alternative to anti-VEGF drugs, to be employed when other measures have failed.

A young woman is suffering from a condition that leaves her blind, but only for half the time. For the last four years, Natalie Adler's eyes have regularly clamped shut for three days every week, and then reopened for the next three days.

A broad expression of the normally selectively-expressed photosensitive protein melanopsin in retinal ganglion cells can restore vision in mice with photoreceptor degeneration, as reported in a study published in the October 14 issue of the Proceedings of the National Academy of Sciences.

Vitrectomy should only be used for patients with diabetic macular oedema (DME) who also display signs of vitreomacular traction, according to study results published in the October issue of Eye.

The iSpheric Model YA-60BB intraocular lens (IOL) (Hoya) has received FDA approval.

Those suffering from thyroid disorders may also be at increased risk of glaucoma, according to study results published online ahead of print by the British Journal of Ophthalmology.

On World Sight Day, Windows to Health, the Pfizer UK initiative to promote regular eye test attendance, unveiled results of the All Eyes on Glaucoma survey, which highlighted the UK's ignorance around glaucoma and its prevention.

iSONEP (sonepcizumab), Lpath, Inc's drug candidate for treating age-related macular degeneration (AMD), has been administered to the first patients in its Phase I trial.

The fixed combination of brimonidine/timolol is more cost effective than dorzolamide/timolol, according to a study published in the September/October issue of the European Journal of Ophthalmology.

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.

The intellectual property dispute between Carl Zeiss Meditec and Optovue has been resolved by the companies, ahead of the legal case reaching court.

Alcon is continuing to invest heavily in its future drug portfolio by forging links with GlaxoSmithKline (GSK) for the global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor, and by expanding an existing alliance with Origenis GmbH for the discovery and development of small molecules.

QLT091001 (QLT Inc), a synthetic retinoid, has begun a Phase I safety study. The orally administered compound is designed to replace 11-cis-retinal, a part of the retinoid-rhodopsin cycle that is essential for visual function, in Leber's Congenital Amaurosis (LCA) sufferers.

Akten Ophthalmic Gel 3.5%, a topical anaesthetic for the eye, has become the first new ocular anaesthetic to receive FDA approval in 40 years, according to a statement released by Akorn, Inc, the maker of Akten.

Sirion has announced the preliminary results of the clinical trial comparing the safety and efficacy of Durezol (difluprednate ophthalmic emulsion; Sirion) with that of Pred Forte (prednisolone acetate ophthalmic suspension; Allergan) for the treatment of anterior segment uveitis.